American Journal of Obstetrics & Gynecology
Volume 201, Issue 2 , Pages 188.e1-188.e7 , August 2009

Risk of invasive cervical cancer in relation to management of abnormal Pap smear results

  • Lena Silfverdal, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Umeå University Hospital, Umeå, Sweden
    • ,
  • Levent Kemetli, MSci

      Affiliations

    • Cancer Screening Unit, Oncologic Center, Karolinska University Hospital, Stockholm, Sweden
    • ,
  • Bengt Andrae, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Gävle Hospital, Gävle, Sweden
    • ,
  • Pär Sparén, PhD

      Affiliations

    • Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
    • ,
  • Walter Ryd, MD, PhD

      Affiliations

    • Department of Pathology and Clinical Cytology, Sahlgrenska University Hospital, Göteborg, Sweden
    • ,
  • Joakim Dillner, MD, PhD

      Affiliations

    • Department of Medical Microbiology, Lund University, Malmö University Hospital, Malmö, Sweden
    • ,
  • Björn Strander, MD, PhD

      Affiliations

    • Oncologic Center, Sahlgrenska University Hospital, Göteborg, Sweden
    • ,
  • Sven Törnberg, MD, PhD

      Affiliations

    • Cancer Screening Unit, Oncologic Center, Karolinska University Hospital, Stockholm, Sweden

Received 1 October 2008 ,Revised 24 January 2009 ,Accepted 10 April 2009.

References 

  1. Gustafsson L, Ponten J, Zack M, Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control. 1997;8:755–763
  2. Carmichael JA, Jeffrey JF, Steele HD, Ohlke ID. The cytologic history of 245 patients developing invasive cervical carcinoma. Am J Obstet Gynecol. 1984;148:685–690
  3. Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer: the national coordinating network for cervical screening working group. Br J Cancer. 1996;73:1001–1005
  4. Sung HY, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer. 2000;88:2283–2289
  5. Andrae B, Kemetli L, Sparen P, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 2008;100:622–629
  6. Andersson-Ellstrom A, Seidal T, Grannas M, Hagmar B. The pap-smear history of women with invasive cervical squamous carcinoma: a case-control study from Sweden. Acta Obstet Gynecol Scand. 2000;79:221–226
  7. Wright TC, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287:2120–2129
  8. Colposcopy and Programme Management. Guidelines for National Health Service cervical screening programme. National Health Service Cervical Screening Programme publication no. 20, 2004. Available at: http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp20.pdf. Accessed Sept. 15, 2007.
  9. Bentley E, Cotton SC, Cruickshank ME, et al. Refining the management of low-grade cervical abnormalities in the UK National Health Service and defining the potential for human papillomavirus testing: a commentary on emerging evidence. J Low Genit Tract Dis. 2006;10:26–38
  10. Rylander E, Rådberg T. To prevent cervical, vaginal and vulvar cancer–guidelines. [in Swedish]. Report no. 34 In: Stockholm: Swedish Society of Obstetrics and Gynecology; 1997;p. 67
  11. Mattsson B, Wallgren A. Completeness of the Swedish cancer register: non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol. 1984;23:305–313
  12. Bolger BS, Lewis BV. A prospective study of colposcopy in women with mild dyskaryosis or koilocytosis. Br J Obstet Gynaecol. 1988;95:1117–1119
  13. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293–299
  14. Soutter WP, Wisdom S, Brough AK, Monaghan JM. Should patients with mild atypia in a cervical smear be referred for colposcopy?. Br J Obstet Gynaecol. 1986;93:70–74
  15. Giles JA, Deery A, Crow J, Walker P. The accuracy of repeat cytology in women with mildly dyskaryotic smears. Br J Obstet Gynaecol. 1989;96:1067–1070
  16. Soutter WP, Fletcher A. Invasive cancer of the cervix in women with mild dyskaryosis followed up cytologically. BMJ. 1994;308:1421–1423
  17. Nygard JF, Sauer T, Skjeldestad FE, Skare GB, Thoresen SO. CIN 2/3 and cervical cancer after an ASCUS pap smear: a 7-year, prospective study of the Norwegian population-based, coordinated screening program. Acta Cytol. 2003;47:991–1000
  18. Flannelly G, Anderson D, Kitchener HC, et al. Management of women with mild and moderate cervical dyskaryosis. BMJ. 1994;308:1399–1403
  19. Shafi MI, Luesley DM, Jordan JA, Dunn JA, Rollason TP, Yates M. Randomized trial of immediate versus deferred treatment strategies for the management of minor cervical cytological abnormalities. Br J Obstet Gynaecol. 1997;104:590–594
  20. The ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol. 2003;188:1393–1400
  21. The ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003;188:1383–1392
  22. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Management of minor cervical cytological abnormalities: a systematic review and a meta-analysis of the literature. Cancer Treat Rev. 2007;33:514–520
  23. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998;92:727–735
  24. Forss A, Tishelman C, Widmark C, Sachs L. Women's experiences of cervical cellular changes: an unintentional transition from health to liminality?. Soc Health Illn. 2004;26:306–325
  25. Kennedy AW, Salmieri SS, Wirth SL, Biscotti CV, Tuason LJ, Travarca MJ. Results of the clinical evaluation of atypical glandular cells of undetermined significance (AGCUS) detected on cervical cytology screening. Gynecol Oncol. 1996;63:14–18
  26. Mohammed DK, Lavie O, de B Lopez A, Cross P, Monaghan JM. A clinical review of borderline glandular cells on cervical cytology. BJOG. 2000;107:605–609
  27. Bigrigg MA, Codling BW, Pearson P, Read MD, Swingler GR. Colposcopic diagnosis and treatment of cervical dysplasia at a single clinic visit: experience of low-voltage diathermy loop in 1000 patients. Lancet. 1990;336:229–231
  28. Nygard JF, Sauer T, Nygard M, Skare GB, Thoresen SO. CIN 2/3 and cervical cancer in an organized screening programme after an unsatisfactory or a normal Pap smear: a seven-year prospective study of the Norwegian population-based screening programme. J Med Screen. 2004;11:70–76
  29. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol. 2005;99(Suppl):S7–S11

 Funded by the Swedish Cancer Society.

 Reprints not available from the authors.

 Cite this article as: Silfverdal L, Kemetli L, Andrae B, et al. Risk of invasive cervical cancer in relation to management of abnormal Pap smear results. Am J Obstet Gynecol 2009;201:188.e1-7.

PII: S0002-9378(09)00392-5

doi: 10.1016/j.ajog.2009.04.006

American Journal of Obstetrics & Gynecology
Volume 201, Issue 2 , Pages 188.e1-188.e7 , August 2009

Article Tools

* Image Usage & Resolution